Asset Manager Exits Shares of Hims & Hers Health

BLKBRD Asset Management sold all 318,666 shares of Hims & Hers (NYSE: HIMS) — an estimated $18.07M trade — fully liquidating a position that was 5.0% of the fund’s AUM and creating a 24.3% swing in 13F-reportable AUM. HIMS traded at $16.30 (Feb 13, 2026) and is down ~72.46% over the past year amid a terminated partnership and lawsuit with Novo Nordisk; a March 10 re‑partnering lifted the stock ~6%. The exit signals institutional de‑risking and amplifies downside risk despite the recent positive partnership update.

Analysis

A concentrated fund liquidation of a mid-cap telehealth name materially increases short-term technical vulnerability for that stock and the sub-sector; expect transient liquidity vacuums that amplify intraday moves as algos, margin desks and other concentrated managers rebalance into large-cap, high-liquidity names. That dynamic tends to compress bid depth in the mid-cap while pushing notional into mega-caps (where execution is cheaper), creating an exploitable divergence between fundamentals and price action over days-to-weeks.

The combination of headline legal/regulatory noise around novel drug distribution and a restructured commercial relationship creates a binary timeline: near-term direction is dominated by litigation status and distribution cadence (days–weeks), while sustainable revenue/GM recovery depends on demonstrated Rx flow and unit economics (quarters). High short-interest and episodic flow risk raise the probability of violent squeezes on good-news updates, even as conviction on steady-state margin recovery remains low.

Second-order beneficiaries are highly liquid healthcare aggregators and the manufacturer that regained distribution rights—these players capture stable order flow and pricing leverage while the mid-cap platform bears the inventory/fulfillment operational risk. Conversely, fintech/marketing vendors that sold customer acquisition services to the mid-cap may face delayed cash conversion and higher churn costs if subscription economics reprice.

Net: tactical trades should be calibrated to event-risk (lawsuit resolution, distribution KPIs, upcoming earnings) with tight sizing; strategic positions require evidence of normalized LTV:CAC and persistent Rx volumes before lifting exposure beyond a watch-sized allocation.

Key Decisions for Investors

• Pair trade (30–90 days): long NVDA / short HIMS, notional ratio 1:1; size to 0.5% NAV. Rationale: capture flow into liquid mega-caps and continued fundamental divergence. Target 15–25% relative return, stop if pair moves against by 8% (absolute).
• Event-driven options (45 days): buy HIMS 45-day put spread (buy 1x OTM put / sell 1x further OTM put) sized to max 0.25% NAV to hedge headline downside while limiting cost. Reward: asymmetric payoff if litigation/news reverts price; max loss = premium.
• Contrarian tactical (90 days): small long HIMS call spread (buy nearer-term OTM / sell higher OTM) sized 0.2% NAV ahead of confirmed distribution KPIs or quarter results—use only after observing two consecutive weeks of normalized Rx fill rates. Aim 3:1 upside/downside with hard 50% trailing loss cut.
• Long NVO (6–12 months): accumulate on weakness as the manufacturer benefits structurally from restored access to platform distribution and reduced legal overhang; size to 0.5–1.0% NAV. Risk: pharma pricing/regulatory actions; target 20–30% upside with 12–18 month horizon.